stockrow
Friday 6 November 2026
Export CDIO’s income statement to Excel — free account
Cardio Diagnostics Holdings, Inc.
CDIO Healthcare Biotechnology
Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024.
- Revenue
- +23.8%
- EPS
- +47.4%
- Free cash flow
- +2.59%
Quarter to September 2026, against a year earlier
1.65
0.03
−1.79%
Follow CDIO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
318.47 | 331.71 | 443.93 | 367.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.48) | (3.55) | (4.83) | (3.71) | |
P/B ratio |
0.68 | 0.62 | 0.87 | 0.98 | |
Price to Tangible BV |
0.68 | 0.62 | 0.87 | 0.98 | |
EV/Sales |
(24.52) | (92.06) | 61.27 | 109.89 | |
EV/EBITDA |
0.06 | 0.25 | 0.00 | 0.00 | |
EV/Operating CF |
0.06 | 0.26 | (0.16) | (0.29) | |
EV/FCF |
0.06 | 0.25 | (0.15) | (0.28) | |
Quick Ratio |
8.46 | 14.41 | 15.56 | 15.81 | |
Current Ratio |
9.79 | 15.76 | 17.15 | 17.44 | |
Net Debt/EBITDA |
3.73 | 4.19 | 3.98 | 2.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 0.87 | 0.89 | 0.88 | |
Capex/Depreciation |
0.00 | (0.02) | 0.00 | 0.00 | |
Interest Coverage |
(636.17) | (524.94) | (440.62) | (754.54) | |
Research and Development Expense of Revenue |
9,552.78% | 4,807.41% | 3,016.67% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
30,877.78% | 61,192.59% | 24,722.22% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
666.67% | 914.81% | 451.85% | 677.94% | |
Graham Net Nets |
1.08 | 1.28 | 0.87 | 0.71 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(137.27%) | (173.33%) | (133.33%) | (153.68%) | |
Free Cash Flow Yield |
(124.63%) | (109.62%) | (89.86%) | (105.76%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.78) | (0.55) | (0.45) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.78) | (0.55) | (0.45) | 0.00 | |
Cash per Share |
2.92 | 2.49 | 1.89 | 0.00 | |
Shareholders Equity per Share |
3.98 | 3.13 | 2.51 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
3.98 | 3.13 | 2.51 | 0.00 | |
Free Cash Flow |
(1.36) | (1.56) | (1.34) | (1.52) | |
Working Capital |
5.32 | 7.25 | 5.80 | 4.10 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | — | |
Net Current Asset Value |
5.13 | 7.09 | 5.66 | 3.99 | |
EV/EBIT |
0.06 | 0.23 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.67 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.01 | 0.01 | 0.01 | 0.01 | |
Average Payables |
0.09 | 0.12 | 0.09 | 0.14 | |
Average Assets |
9.19 | 10.92 | 9.16 | 7.44 | |
Average Common Equity |
8.27 | 10.14 | 8.58 | 6.93 |
Columns are period end dates · fundamentals updated 6 Nov 2026